EMT, as a key factor of malignant glioma invasion enhancement, can be characterized by an increase in the expression of biomarkers, such as CDH2, VIM, FN1, SNAI1, SNAI2, ACTA2, and so on [55]. The gene discussed is CDH2; the disease is malignant glioma.